Bolt Biotherapeutics
BOLT
65 hedge funds and large institutions have $84.8M invested in Bolt Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 13 closing their positions.
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
5% more funds holding
Funds holding: 62 → 65 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.61% less ownership
Funds ownership: 4.51% → 3.89% (-0.61%)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
49% less capital invested
Capital invested by funds: $165M → $84.8M (-$79.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.35M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.05M |
| 3 |
HCM
Hawkeye Capital Management
Miami Beach,
Florida
|
+$831K |
| 4 |
Renaissance Technologies
New York
|
+$677K |
| 5 |
ESCM
Echo Street Capital Management
New York
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.76M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.98M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.98M |
| 5 |
Goldman Sachs
New York
|
-$1.46M |
BOLT Hedge Fund Activity: Q1 2022 in Review
65 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2022, worth a combined $84.8M — down 49% from $165M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BOLT positions and 13 closed out — a net gain of 3 holders — while 13 added to existing stakes and 23 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.7M sold.
- 65 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2022, up from 62 in Q4 2021.
- Funds reported $84.8M of Bolt Biotherapeutics stock for Q1 2022, down 49% quarter-over-quarter.
- 16 funds opened new Bolt Biotherapeutics positions in Q1 2022 and 13 closed out, a net change of +3 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2022 was Armistice Capital, an estimated $1.35M added.
- The largest Bolt Biotherapeutics seller in Q1 2022 was RA Capital Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2022.